Abstract:Background Proliferating cell nuclear antigen (PCNA) is essential for DNA replication and repair, cell growth, and survival. PCNA also enhances androgen receptor (AR) signaling in prostate cancer (PC) cells. We identified a PCNA interaction protein (PIP) box at the N‐terminal domain of AR and developed a small peptide PCNA inhibitor R9‐AR‐PIP containing AR PIP‐box. We also identified a series of small molecule PCNA inhibitors (PCNA‐Is) that bind directly to PCNA and interrupt PCNA functions. The present study investigated the effects of the PCNA inhibitors on the sensitivity of PC cells to X‐ray radiation. Methods The effects of targeting PCNA on radio sensitivity of PC cells were investigated in four lines of castration‐resistant PC (CRPC) cells with different AR expression statuses. The cells were treated with the PCNA inhibitors and X‐ray radiation alone or in combination. The effects of the treatment on expression of AR target genes, DNA damage response, DNA damage, homologous recombination repair (HRR), and cytotoxicity were evaluated. Results We found that the androgen response element (ARE) occupancy of the DNA damage response gene PARP1 by AR is significantly attenuated by PCNA‐I1S or R9‐AR‐PIP combined with X‐ray radiation, while X‐ray radiation alone does not enhance the ARE occupancy. PCNA‐I1S or R9‐AR‐PIP alone significantly inhibits occupancy of the AR‐occupied regions (AROR) in PRKDC and XRCC2 genes. R9‐AR‐PIP and PCNA‐I1S inhibit expression of AR‐Vs target gene cyclin A2 and show the additive effects with radiation in AR‐positive CRPC cells. Targeting PCNA by PCNA‐I1S and R9‐AR‐PIP downregulates expression of DNA damage response genes EXO1, Rad54L, Rad51, and/or PARP1 and shows the additive effects with radiation as compared with their respective controls in AR‐positive CRPC LNCaP‐AI, 22Rv1, and R1‐D567 cells, but not in AR‐negative PC‐3 cells. R9‐AR‐PIP and PCNA‐I1S elevate the levels of phospho‐DNA‐PKcs(S2056) and γH2AX, indicating DNA damage in response to radiation in AR‐positive cells. The HRR is significantly attenuated by PCNA inhibitors PCNA‐I1S, R9‐AR‐PIP, and T2AA in all four CRPC cells examined, and inhibited by Enzalutamide (Enz) only in 22RV1 cells. The cytotoxicity induced by X‐ray radiation in androgen‐dependent LNCaP cells is enhanced by Enz and a lower concentration of R9‐AR‐PIP in the colony formation assay. R9‐AR‐PIP at higher concentration reduces the colony formation and has an additive effect with X‐ray radiation in all AR expressing cells, regardless of AR‐FL and AR‐Vs, but does not significantly alter the colony formation in AR‐negative PC‐3 cells. PCNA‐I1S attenuates colony formation and has an additive effect with ionizing radiation in all four CRPC cells, regardless of AR expression status. Conclusion These data provide a strong rationale for the therapy studies using PCNA‐I1S or R9‐AR‐PIP in combination with X‐ray radiation against CRPC tumors in preclinical models.

Target Validation and Structure-Activity Analysis of A Series of Novel Pcna Inhibitors

Antitumor effects of a novel small molecule targeting PCNA chromatin association in prostate cancer.

Abstract 5784: Structure-based drug design against caPCNA for selective cancer chemotherapy development

Abstract 6583: Developing a selective cancer chemotherapy by small molecule-based targeting of PCNA protein

Additive Effects of a Small Molecular PCNA Inhibitor PCNA-I1S and DNA Damaging Agents on Growth Inhibition and DNA Damage in Prostate and Lung Cancer Cells

Identification, Structure–Activity Relationships of Marine-Derived Indolocarbazoles, and a Dual PKCθ/δ Inhibitor with Potent Antipancreatic Cancer Efficacy

PARP1: A Promising Target for the Development of PARP1-based Candidates for Anticancer Intervention

Inhibition of DNA replication by an anti-PCNA aptamer/PCNA complex

PCNA: a silent housekeeper or a potential therapeutic target?

Structure-based Discovery of Novel CK2α-Binding Cyclic Peptides with Anti-cancer Activity.

Abstract 4481: Enhancing AOH1996 through structure activity relationship exploration for caPCNA inhibition

Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (Adp-Ribose) Polymerase-1 (PARP-1) Inhibitors

Synthesis and in Vitro Biological Evaluation of 3-Ethyl-1,5-naphthyridin-2(1h)-one Derivatives As Potent PARP-1 Selective Inhibitors and PARP-1 DNA Trappers

Targeting proliferating cell nuclear antigen enhances ionizing radiation‐induced cytotoxicity in prostate cancer cells

Discovery of Novel Benzamide Derivatives Bearing Benzamidophenyl and Phenylacetamidophenyl Scaffolds As Potential Antitumor Agents Via Targeting PARP-1.

Discovery, Design and Synthesis of 6H-Anthra[1,9-cd]isoxazol-6-one Scaffold As G9a Inhibitor Through a Combination of Shape-Based Virtual Screening and Structure-Based Molecular Modification

Synthesis, SAR Study and Biological Evaluation of Novel Pyrazolo[1,5-A]pyrimidin-7-yl Phenyl Amides As Anti-Proliferative Agents

Small molecule targeting of transcription-replication conflict for selective chemotherapy

Design, Synthesis, Biological Evaluation and Molecular Docking Study of Novel Urea-Based Benzamide Derivatives As Potent Poly(adp-Ribose) Polymerase-1 (PARP-1) Inhibitors

Design, Synthesis and Anticancer Evaluation of Selective 2,4-Disubstituted Pyrimidine CDK9 Inhibitors

Design, Synthesis and Antitumor Activity Study of PARP-1/HDAC Dual Targeting Inhibitors.